RIPK2 and inflammatory bowel disease: Because of the role of NOD2 in mucosal tissue in IBD patients (Stronati et al., 2008), therapeutic targeting the NOD2/RIPK2 pathway holds potentials to reestablish gut tissue homeostasis (Parlato and Yeretssian, 2014; Rathinam and Chan, 2018).